Available now to every subscription customer

A pipeline,
not a prompt.

The ELTON pipeline just got significantly bigger, and it is now available to every subscription customer at no additional cost. We enable it customer by customer, so it is not switched on until you say so. Your data never becomes anyone’s prompt, and no finding reaches you until a person has reviewed it.

No additional costHuman reviewedYour data stays inside
YOUR SUBSCRIPTION FEE Unchanged fixed annual nothing to buy WHAT GREW INSIDE IT Testing volumemore, every release was Time to findingsdays, not weeks Coverage and traceabilitysubmission grade consultants bill per test · we pass the gain to you
Next step · September 2026

Want it on? Start with the webinar.

We enable the pipeline customer by customer. The explainer session walks through how it works, where your data goes, and how to pick your first products.

Wed, September 16, 2026 · 11:00 AM ET
Reserve your seat
Existing customers · 45 min + Q&A
What this is

Thirteen years of device testing, written into a toolchain.

Vulnerabilities in a medical device live in software, hardware, firmware, applications, interfaces, and the connections to everything else in the system. We have been testing those products since 2013. That experience is now a toolchain that runs continuously against your releases.

No additional cost

Included in the subscription you already have. Consulting firms bill per test, so more capability costs you more. We do not, so the gain goes to you: more work on your behalf, same fixed fee.

Quality is sustained

Human review and tester knowledge sit in front of every result. No issue the pipeline surfaces is ever passed directly to you.

Built for regulated products

A medical device harness and a real classification model, so what you receive is a short list that matters, with coverage and traceability a reviewer will accept.

Set the record straight

The difference between a prompt and a pipeline.

You may have heard vendors describe AI testing. Pointing a model at a product and asking it to find vulnerabilities is not testing. It is a prompt, and anyone can write one. Testing is about tools. We use AI to build the tools, decide which ones to run, combine what they return, and reason over the results.

A PROMPT What anyone can do in a chat client. chat client pasted › firmware_main.c pasted › architecture.pdf pasted › prior findings “find vulnerabilities in this” your data leaves Public model no device context WHAT COMES BACK non-deterministic · unverified · no traceability a wall of maybe-issues few real THE PIPELINE Thousands of hours of engineering. AI writes the tools, 24/7 R&D only. It never sees your product data. ships tools into SEALED · YOUR DATA STAYS HERE Digital twinyour release Orchestratorpicks the tools Tools runon the device DETERMINISTIC TOOLCHAIN + thousands WHAT COMES BACK repeatable · verified on device · human reviewed
Left: your data becomes the input to a general model. Right: AI builds the tools, and your data stays inside the pipeline.
Why a prompt fails here

It has no device context, verifies nothing, and returns something different every time you ask. The output is a wall of maybe-issues with no evidence a reviewer can follow, and getting there meant handing over your source code.

Why the pipeline works

Tools are deterministic. They run the same way twice, against the real device, and produce evidence. The engineering is the hard part, and it is where thousands of hours have gone.

The edge, and where it comes from

Five agentic loops, writing code around the clock.

This is the part that is hard to copy. More than five agentic loops run continuously, every hour of every day, finding gaps in our own testing coverage and writing new tools to close them. That is the edge, and because you are on a subscription, it is your edge too.

ONE LOOP, RUNNING NON-STOP Find the gap Write the code Test it Ship the tool 5 LOOPS IN PARALLEL no meter · no scoping call · no end date WHAT THEY ARE BUILDING Protocol toolingDICOM, HL7, proprietary linksFirmware toolingunpackers, emulators, debuggersHardware interfacesUART, JTAG, SPI, radioApplication layermobile, web, API surfacesExploit validationproving it on the real device THE TOOLCHAIN 1,000s of tools that know how to test a medical device and counting SHARED WITH YOU Once enabled, every new tool runs on your releases. Same fee.
Five loops, always running. Every tool they ship joins the toolchain, ready to run on your releases once the pipeline is enabled for them.
Why this was impossible before

Building a debugger for one stubborn process, or a MITM for one proprietary protocol, used to consume an entire assessment budget. Now it takes minutes, the cost is one time, and the tool is reused on every device after.

Why it compounds

A prompt starts from zero every time you open it. The toolchain does not. Every loop, every day, it gets deeper on medical devices specifically, and that gap widens rather than closes.

Your data

We ask a model to write a tool. We never ask it about you.

This is the part worth being precise about. Your source code, firmware, documents and findings stay inside the pipeline. What goes to a model is our own engineering work: what a tool needs to do, and how a documented protocol behaves.

STAYS INSIDE ELTON never sent to any model, ever Source codeprovided under NDAFirmware imagesbinaries and unpackedArchitecture documentsdesign and protocol docsFindings and evidenceyour vulnerability recordThe digital twinyour release, modeled GOES TO A MODEL our own engineering work, nothing of yours Tool specificationswhat a tool must doProtocol descriptionspublic standardsELTON’s own codethe harness we wroteTest logichow to exercise an interface We ask a model to write a tool. We never ask it about you. no crossing
A hard boundary, not a policy promise. The data path and the development path never meet.
Worth asking any vendorWhen someone says they use AI on your product, ask where your data goes. If the answer is a general chat client, it left their control the moment they pressed send.
End to end

More findings, better sorted.

More tools surface more issues. The pipeline then decides what each one actually is: directly exploitable, conditionally exploitable, or a weakness with no path today. Doing that in days is the point.

HOW A TEST ACTUALLY RUNS 01Digital twinyour release, modeled02Orchestratorselects and sequences03Tools executeon the real device04Combinededupe and correlate 05 Human review gate nothing reaches you unreviewed CLASSIFIED, NOT DUMPED ON YOU Directly exploitablefix now, with a prescriptive code-level fixConditionally exploitabletracked, with the condition namedWeaknessno path today, defensibly documented more findings, better sorted · days, not weeks
Twin, orchestrator, tools on the device, combine, human gate, then classification and a fix.
Why we ask for deeper access

Find them first, then label them honestly.

Privileged runtime, service processes, service tools, protocol documentation, code. The pipeline is not bound by time, so the more it can reach, the more it surfaces. Knowing more is only a burden if everything gets called a vulnerability.

DEEPER ACCESS, MORE FOUND FIRST Black boxsurface only+ Service tools and processes+ Protocol documentation+ Privileged runtime and codedeepest what we can reach before anyone else does An attacker without that access finds the same issues, only slower. We would rather be first.
Knowing more is not regulatory debt

It becomes debt only if you call everything a vulnerability. Conditions let us separate what is exploitable from what is not, so you carry the risk you actually have and can defend the rest.

A weakness today is a head start tomorrow

When a directly exploitable vulnerability later lands on that product, we already know whether something we classified as a weakness just became reachable.

And it makes the fix better

That same depth is what lets us prescribe the change rather than throw another issue over the fence. Fixing things is the point of testing.

Why this is all upside

Three reasons this is a net gain for you.

01 · Stay ahead of discovery

Researchers, customers and adversaries now have discovery techniques that used to require deep expertise. Staying ahead of what they will find is not optional, and the pipeline is how we get there first.

02 · More value on the same subscription

Per-test vendors have every reason to keep the test small. We are on a subscription, so capability turns directly into more testing on your behalf, continuously, at no additional cost.

03 · Better FDA evidence

The traceability and coverage this produces would cost hundreds of thousands to assemble by hand. You get it as a byproduct of the work rather than a separate project.

The short version

AI writes the tools.
The pipeline does the testing.

A prompt is something anyone can write in an afternoon. A pipeline is thirteen years of knowing where medical devices break, turned into software that runs every day.

How to switch it on

Available to you. Not on by default.

We enable the expanded pipeline customer by customer so we can agree the access, scope and what your findings will look like afterwards. If you are a subscription customer and want it, start with the explainer session in September.

Inside the ELTON Pipeline · Wednesday, September 16, 2026 · 11:00 AM ET · existing customers only

Exploitability management for medical devices. FDA §524B methodologyExploitability proven at runtime95% faster than legacy testing Book a Demo
Platform
Platform OverviewDigital TwinAutonomous TestingExploitability VerificationVulnerability GraphRemediation OptimizationELTON TestLink™Lifecycle & MetricsCVSSv4 MigrationProduct Tour
Solutions
FDA §524BEU MDR/CRAEU REDNIS2IMDRF N60 / N73Japan MHLWPostmarket SurveillanceIncident ResponseSecurity EngineeringRegulatory Affairs
Why ELTON
Why ELTONProof Over ProbabilityFind the 1%Not a Pentest. Not a Scanner.MDDT MethodologyCredentialsDevice ModalitiesPricingELTON vs. Consultants
Resources
FDA Deficiency ListFDA Testing RequirementsFDA Cyber SOPs & TemplatesRegulatory GuidesWebinarsThe Death of PentestingThe AI Vulnerability ExplosionSecurity AdvisoriesWhitepapersIntelligence & Blog
Company
AboutLeadershipCareersContact Book a Demo